An imaging-based risk calculator for prediction of conversion to psychosis in clinical high-risk individuals using glutamate 1H MRS

[1]  J. Bustillo,et al.  The Meaning of Glutamate and the Quest for Biomarkers in the Transition to Psychosis. , 2019, JAMA psychiatry.

[2]  P. McGuire,et al.  Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis , 2019, JAMA psychiatry.

[3]  J. Lieberman,et al.  Prevalence and phenomenology of violent ideation and behavior among 200 young people at clinical high-risk for psychosis: an emerging model of violence and psychotic illness , 2018, Neuropsychopharmacology.

[4]  Tobias Navarro Schröder,et al.  Resting-state gamma-band power alterations in schizophrenia reveal E/I-balance abnormalities across illness-stages , 2018, eLife.

[5]  S. Rauch,et al.  Clinical Applications of Neuroimaging in Psychiatric Disorders. , 2018, The American journal of psychiatry.

[6]  R. Bagby,et al.  Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis , 2018, Neuropsychopharmacology.

[7]  J. Lieberman,et al.  A predictive model for conversion to psychosis in clinical high-risk patients , 2018, Psychological Medicine.

[8]  S. A. Wijtenburg,et al.  Glutamatergic metabolites among adolescents at risk for psychosis , 2017, Psychiatry Research.

[9]  A. Graff-Guerrero,et al.  Prefrontal and Striatal Gamma-Aminobutyric Acid Levels and the Effect of Antipsychotic Treatment in First-Episode Psychosis Patients , 2017, Biological Psychiatry.

[10]  A. Grace,et al.  Cortical GABA in Subjects at Ultra-High Risk of Psychosis: Relationship to Negative Prodromal Symptoms , 2017, The international journal of neuropsychopharmacology.

[11]  Paolo Fusar-Poli,et al.  Development and Validation of a Clinically Based Risk Calculator for the Transdiagnostic Prediction of Psychosis , 2017, JAMA psychiatry.

[12]  P. McGuire,et al.  Improving Prognostic Accuracy in Subjects at Clinical High Risk for Psychosis: Systematic Review of Predictive Models and Meta-analytical Sequential Testing Simulation , 2016, Schizophrenia bulletin.

[13]  Tyrone D. Cannon,et al.  An Individualized Risk Calculator for Research in Prodromal Psychosis. , 2016, The American journal of psychiatry.

[14]  A. Aleman,et al.  Prefrontal NAA and Glx Levels in Different Stages of Psychotic Disorders: a 3T 1H-MRS Study , 2016, Scientific Reports.

[15]  J. Reichenbach,et al.  Associations of hippocampal metabolism and regional brain grey matter in neuroleptic-naïve ultra-high-risk subjects and first-episode schizophrenia , 2015, European Neuropsychopharmacology.

[16]  A. Graff-Guerrero,et al.  Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy , 2015, The international journal of neuropsychopharmacology.

[17]  Tyrone D. Cannon,et al.  The content of attenuated psychotic symptoms in those at clinical high risk for psychosis , 2014, Psychiatry Research.

[18]  H. Yamasue,et al.  Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia. , 2014, Schizophrenia bulletin.

[19]  D. Ffytche,et al.  Visual Hallucinations in the Psychosis Spectrum and Comparative Information From Neurodegenerative Disorders and Eye Disease , 2014, Schizophrenia bulletin.

[20]  R. Murray,et al.  Relationship Between Brain Glutamate Levels and Clinical Outcome in Individuals at Ultra High Risk of Psychosis , 2014, Neuropsychopharmacology.

[21]  A. Graff-Guerrero,et al.  Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. , 2013, JAMA psychiatry.

[22]  A. Graff-Guerrero,et al.  Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study. , 2013, The international journal of neuropsychopharmacology.

[23]  A. Graff-Guerrero,et al.  Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis , 2011, Neuropsychopharmacology.

[24]  Dennis Velakoulis,et al.  Hippocampal pathology in individuals at ultra-high risk for psychosis: A multi-modal magnetic resonance study , 2010, NeuroImage.

[25]  Philip K. McGuire,et al.  Glutamate Dysfunction in People with Prodromal Symptoms of Psychosis: Relationship to Gray Matter Volume , 2009, Biological Psychiatry.

[26]  Tyrone D. Cannon,et al.  Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. , 2007, Schizophrenia bulletin.

[27]  S. Provencher.  Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[28]  J. Lieberman,et al.  A Longitudinal Study of Violent Behavior in a Psychosis-Risk Cohort , 2018, Neuropsychopharmacology.

[29]  J. Lieberman,et al.  Distinct Relationships Between Visual and Auditory Perceptual Abnormalities and Conversion to Psychosis in a Clinical High-Risk Population , 2017, JAMA psychiatry.

[30]  Godfrey D Pearlson,et al.  Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. , 2003, Schizophrenia bulletin.

[31]  Karl J. Friston,et al.  Spatial registration and normalization of images , 1995 .